Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
King Faisal Specialist Hospital And Research Centre operates in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action indicates a focused and limited engagement with the patent office, likely centered on a specific Biotechnology & Pharmaceuticals innovation. The prosecution is being handled by 1 distinct examiner, BAUSCH, SARAE L, who is also the busiest examiner for the portfolio. This concentration suggests that the institution's current intellectual property efforts are being evaluated by the official, allowing for a very targeted legal strategy that focuses on the specific requirements of the examiner. Practitioners can observe that the prosecution efforts are not currently spread across different concurrent disputes, allowing for a concentrated allocation of legal resources toward this particular matter.
The entire active portfolio is confined to a distinct art unit, reflecting a specialized technological focus. For practitioners, this means that the institution's immediate success in securing patent rights depends entirely on the resolution of the pending office action. Since BAUSCH, SARAE L is the examiner involved, the prosecution strategy can be tailored specifically to the requirements and interpretive style of the individual. The focus within the Biotechnology & Pharmaceuticals field suggests that King Faisal Specialist Hospital And Research Centre is prioritizing a specific set of innovations at this time, and the outcome of the pending action will be a significant determinant of the immediate patenting success. Understanding the examiner's previous rulings will be essential to anticipate the trajectory of this portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUSCH, SARAE L | 1 | 29.8% | +44.7% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324563 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | BAUSCH, SARAE L | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18122839 | COMBINATIONS OF AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, A PLATINUM-BASED ANTINEOPLASTIC DRUG, AND A TAXANE | XIAO, YAN | 15d |
| 18324563 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | BAUSCH, SARAE L | 21d |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324563 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | BAUSCH, SARAE L | 1699 | §101§102§103 | Final Rejection | 21d | Pending | May 26, 2023 |
| 18122839 | COMBINATIONS OF AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, A PLATINUM-BASED ANTINEOPLASTIC DRUG, AND A TAXANE | XIAO, YAN | 1642 | §103 | Final Rejection | 15d | Pending | Mar 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial